Furthermore, methylation of the CCN3 promoter was significantly increased in peripheral blood samples of CML patients compared with healthy controls, but this was unaffected by Imatinib treatment (Vatanmakanian et al. 2019). Here, CCN3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.